Theravance Biopharma, Inc. (TBPH) Stock Price

TBPHStock
$17.03+22.29%52W
Market Cap$884.18M
P/E8.30x
PEG Ratio
Div yield
Beta0.19

TBPH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-22.51%
Price vs S&P 500 (4W)-2.34%
VGM Score62.78
P/E Ratio (Annual)8.30x

TBPH Earnings Surprise History

Q2 25-0.08est. -0.13
Q3 250.04est. -0.05
Q4 250.06est. 0.33
Q1 260.01est. 0.09
Q2 260.18est. 0.07

TBPH Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.92
3.92
3.82
3.73

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
TBPHTheravance Biopharma, Inc.
BBC$17.03
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Theravance Biopharma, Inc.

Theravance Biopharma is a biopharmaceutical company developing organ-selective small-molecule medicines for inflammation and immunology, with a focus on lung-selective drugs for respiratory disease. The company's approach aims to improve the therapeutic index by maximizing efficacy while minimizing systemic side effects. Its portfolio includes YUPELRI (revefenacin), an FDA-approved inhalation solution for COPD maintenance treatment.